Medtronic announces fda approval of its next generation recharge-free spinal cord stimulation platform

Dublin, june 10, 2021 /prnewswire/ -- medtronic plc (nyse: mdt), the global leader in medical technology, today announced it has received u.s. food and drug administration (fda) approval for vanta™, a high performance recharge-free implantable neurostimulator (ins) with a device life that can be optimized up to 11 years. at comparable settings, the vanta neurostimulator offers nearly twice the device life than competitive primary cell devices.1,2 it also utilizes medtronic's proprietary adaptivestim™ technology for personalized pain relief that adapts to the patient's movement or body position using a built-in accelerometer.
MDT Ratings Summary
MDT Quant Ranking